{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:29:57Z","timestamp":1786422597316,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Few studies have compared body composition changes in children living with HIV receiving integrase inhibitors or boosted protease inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Children switching to second-line antiretroviral therapy were randomized to dolutegravir (DTG), darunavir\/ritonavir (DRV\/r), atazanavir\/ritonavir (ATV\/r) or lopinavir\/ritonavir (LPV\/r), and to tenofovir alafenamide (TAF) or standard of care (abacavir or zidovudine) using a factorial design. Body composition was measured using bioelectric impedance analysis over 96 weeks. Associations between baseline characteristics and changes in fat mass, fat-free mass, muscle mass and body fat percentage were estimated using robust regression with multivariable fractional polynomial selection (exit\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Eight hundred forty-one participants were included in the analysis. Females compared with males had greater fat accrual (+4.66% body fat, +1.32\u2009kg fat mass; both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Compared with LPV\/r, ATV\/r and DTG exposures were associated with higher fat-free mass [+0.85\u2009kg (95% confidence interval: 0.43\u20131.27) and +0.79\u2009kg (0.37\u20131.21) respectively] and muscle mass [+0.82\u2009kg (0.41\u20131.23) and +0.82\u2009kg (0.42\u20131.22), respectively] (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). TAF and DRV\/r exposures were associated with higher fat mass [+0.32\u2009kg (0.12\u20130.52)\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002; +0.33\u2009kg (0.04\u20130.61)\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.025, respectively]. Prior nevirapine exposure was also associated with greater fat accrual [+0.36\u2009kg (0.13\u20130.58) vs. efavirenz,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002]. Baseline CD4 and viral load, time on first-line antiretroviral therapy, and site were also associated with composition changes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>DTG and ATV\/r were associated with greater gains in fat-free mass and muscle mass than LPV\/r, while DRV\/r, TAF and prior nevirapine exposure were associated with fat mass accrual. Fat gain may initially reflect return to health but sustained increases may have metabolic implications. These findings suggest the need to monitor fat compartments with long-term exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005195","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:00:30Z","timestamp":1771909230000},"page":"768-775","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2944-5412","authenticated-orcid":false,"given":"Eva","family":"Natukunda","sequence":"first","affiliation":[{"name":"Department of Paediatrics, Joint Clinical Research Centre, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2082-0861","authenticated-orcid":false,"given":"Alex J.","family":"Szubert","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7751-6177","authenticated-orcid":false,"given":"Mutsa","family":"Bwakura-Dangarembizi","sequence":"additional","affiliation":[{"name":"University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1843-8169","authenticated-orcid":false,"given":"Veronica","family":"Mulenga","sequence":"additional","affiliation":[{"name":"University of Zambia School of Medicine, Lusaka, Zambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-0970","authenticated-orcid":false,"given":"Katja","family":"Doerholt","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0761-469X","authenticated-orcid":false,"given":"Abbas","family":"Lugemwa","sequence":"additional","affiliation":[{"name":"Joint Clinical Research Centre, Mbarara, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1538-0014","authenticated-orcid":false,"given":"Spencer","family":"Byaruhanga","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Joint Clinical Research Centre, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5083-5738","authenticated-orcid":false,"given":"Esther","family":"Nambi","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Joint Clinical Research Centre, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wedu","family":"Ndebele","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Mpilo Central Hospital, Bulawayo, Zimbabwe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Nyathi","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Mpilo Central Hospital, Bulawayo, Zimbabwe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-5490","authenticated-orcid":false,"given":"Diana M.","family":"Gibb","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5557-2733","authenticated-orcid":false,"given":"Grace","family":"Ndeezi","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-8509","authenticated-orcid":false,"given":"Ann Sarah","family":"Walker","sequence":"additional","affiliation":[{"name":"Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Musoke","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health, College of Health Sciences, Makerere University, Kampala, Uganda"},{"name":"Makerere University\u2013Johns Hopkins University Research Collaboration (MUJHU Care Ltd), Kampala, Uganda."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7472-9054","authenticated-orcid":false,"given":"Victor","family":"Musiime","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Joint Clinical Research Centre, Kampala, Uganda"},{"name":"Department of Paediatrics and Child Health, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"R1-20260811","doi-asserted-by":"crossref","first-page":"102654","DOI":"10.1016\/j.jiph.2025.102654","article-title":"Cardiovascular disease and its risk factors among people living with HIV: a systematic review and meta-analysis.","volume":"18","author":"Du","year":"2025","journal-title":"J Infect Public Health"},{"key":"R2-20260811","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/ajcn\/nqy049","article-title":"Anthropometric measures of central adiposity are highly concordant with predictors of cardiovascular disease risk in HIV patients.","volume":"107","author":"Beraldo","year":"2018","journal-title":"Am J Clin Nutr"},{"key":"R3-20260811","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/25787489.2020.1848131","article-title":"Changes in central adipose tissue after switching to integrase inhibitors.","volume":"21","author":"Debroy","year":"2020","journal-title":"HIV Res Clin Pract"},{"key":"R4-20260811","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1161\/CIRCULATIONAHA.111.067264","article-title":"Body fat distribution and risk of cardiovascular disease.","volume":"126","author":"Despr\u00e9s","year":"2012","journal-title":"Circulation"},{"key":"R5-20260811","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/QAD.0000000000002421","article-title":"Weight gain in people living with HIV switched to dual therapy: changes in body fat mass.","volume":"34","author":"Vizcarra","year":"2020","journal-title":"AIDS"},{"key":"R6-20260811","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/cid\/ciw017","article-title":"Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s.","volume":"62","author":"McComsey","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R7-20260811","doi-asserted-by":"crossref","first-page":"ofy201","DOI":"10.1093\/ofid\/ofy201","article-title":"Changes in waist circumference in HIV-infected individuals initiating a raltegravir or protease inhibitor regimen: effects of sex and race.","volume":"5","author":"Bhagwat","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"R8-20260811","doi-asserted-by":"crossref","first-page":"e25899","DOI":"10.1002\/jia2.25899","article-title":"Weight gain during the dolutegravir transition in the African Cohort Study.","volume":"25","author":"Esber","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"R9-20260811","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/QAD.0000000000003888","article-title":"Regional variation in weight change after the transition to dolutegravir in Uganda and South Africa.","volume":"38","author":"Migisha","year":"2024","journal-title":"AIDS"},{"key":"R10-20260811","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/INF.0000000000003066","article-title":"Body fat distribution and metabolic changes in a cohort of adolescents living with HIV switched to an antiretroviral regimen containing dolutegravir.","volume":"40","author":"Giacomet","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20260811","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1056\/NEJMoa2404597","article-title":"Second-line antiretroviral therapy for children living with HIV in Africa.","volume":"392","author":"Musiime","year":"2025","journal-title":"N Engl J Med"},{"key":"R12-20260811","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/pr.2015.160","article-title":"LMS tables for waist-circumference and waist-height ratio Z-scores in children aged 5-19 years in NHANES III: association with cardio-metabolic risks.","volume":"78","author":"Sharma","year":"2015","journal-title":"Pediatr Res"},{"key":"R13-20260811","first-page":"36","article-title":"Fat accumulation with pubertal development.","volume":"60","author":"Siervogel","year":"2003","journal-title":"Horm Res"},{"key":"R14-20260811","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3390\/life14111367","article-title":"Weight gain in HIV adults receiving antiretroviral treatment: current knowledge and future perspectives.","volume":"14","author":"Markakis","year":"2024","journal-title":"Life"},{"key":"R15-20260811","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1016\/S2352-3018(18)30361-8","article-title":"Growth in HIV-1-exposed but uninfected infants treated with lopinavir\u2013ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial.","volume":"6","author":"Blanche","year":"2019","journal-title":"Lancet HIV"},{"key":"R16-20260811","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jcb.21882","article-title":"Lopinavir impairs protein synthesis and induces eEF2 phosphorylation via the activation of AMP-activated protein kinase.","volume":"105","author":"Hong-Brown","year":"2008","journal-title":"J Cell Biochem"},{"key":"R17-20260811","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3390\/nu8080473","article-title":"Associations of fat mass and fat-free mass with physical fitness in 4-year-old children: results from the MINISTOP trial.","volume":"8","author":"Henriksson","year":"2016","journal-title":"Nutrients"},{"key":"R18-20260811","doi-asserted-by":"crossref","first-page":"e068427","DOI":"10.1136\/bmjopen-2022-068427","article-title":"Growth patterns in childhood and adolescence and adult body composition: a pooled analysis of birth cohort studies from five low and middle-income countries (COHORTS collaboration).","volume":"13","author":"Poveda","year":"2023","journal-title":"BMJ Open"},{"key":"R19-20260811","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3390\/v16040613","article-title":"Risk of cardiovascular events in people with HIV (PWH) treated with integrase strand-transfer inhibitors: the debate is not over; results of the SCOLTA study.","volume":"16","author":"Corti","year":"2024","journal-title":"Viruses"},{"key":"R20-20260811","first-page":"1","article-title":"Weight gain, body composition and metabolic parameters on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.","volume":"1","author":"Turkova","year":"2025","journal-title":"Preprints Lancet (SSRN)"},{"key":"R21-20260811","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12887-023-04143-6","article-title":"Growth, weight gain and BMI in virally suppressed children on antiretroviral therapy with specific reference to dolutegravir.","volume":"23","author":"Belfrage","year":"2023","journal-title":"BMC Pediatr"},{"key":"R22-20260811","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/archdischild-2012-302633","article-title":"Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.","volume":"98","author":"Arpadi","year":"2013","journal-title":"Arch Dis Child"},{"key":"R23-20260811","doi-asserted-by":"crossref","first-page":"e26371","DOI":"10.1002\/jia2.26371","article-title":"Impact of switching to a dolutegravir-based regimen on body weight changes: insights from West African adult HIV cohorts.","volume":"27","author":"Tiendrebeogo","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"R24-20260811","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cid\/ciae191","article-title":"Antiretrovirals and weight change: weighing the evidence.","volume":"79","author":"Wohl","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R25-20260811","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/infdis\/jis720","article-title":"Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF\u2013emtricitabine with atazanavir-ritonavir or efavirenz: AIDS clinical trials group study A5224s, substudy of A5202.","volume":"207","author":"McComsey","year":"2012","journal-title":"J Infect Dis"},{"key":"R26-20260811","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1468-1293.2010.00823.x","article-title":"Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy.","volume":"11","author":"Chantry","year":"2010","journal-title":"HIV Med"},{"key":"R27-20260811","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1086\/498022","article-title":"CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.","volume":"41","author":"McDermott","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R28-20260811","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1097\/QAD.0000000000001248","article-title":"Long-term body composition changes in antiretroviral-treated HIV-infected individuals.","volume":"30","author":"Grant","year":"2016","journal-title":"AIDS"},{"key":"R29-20260811","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1017\/S000711452400134X","article-title":"Associations of linear growth with body composition of perinatally HIV-infected African adolescents.","volume":"132","author":"Filteau","year":"2024","journal-title":"Br J Nutr"},{"key":"R30-20260811","doi-asserted-by":"crossref","first-page":"e966","DOI":"10.1542\/peds.2011-3020","article-title":"Variability of growth in children starting antiretroviral treatment in southern Africa.","volume":"130","author":"Gsponer","year":"2012","journal-title":"Pediatrics"},{"key":"R31-20260811","doi-asserted-by":"crossref","first-page":"e0003200","DOI":"10.1371\/journal.pgph.0003200","article-title":"Methods for measuring body composition in Zambian adolescents living with HIV.","volume":"4","author":"Filteau","year":"2024","journal-title":"PLOS Glob Public Health"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:00:56Z","timestamp":1786420856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005195","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]}}}